Devonian Health Group Inc. (DVHGF)

USD 0.13

(-6.29%)

Market Cap (In USD)

19.63 Million

Revenue (In USD)

2.34 Million

Net Income (In USD)

-4.59 Million

Avg. Volume

147.00

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.01-0.2138
PE
-
EPS
-
Beta Value
1.217
ISIN
CA2518341078
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Luc D. Gregoire CA, CPA
Employee Count
-
Website
https://groupedevonian.com
Ipo Date
2022-09-19
Details
Devonian Health Group Inc. engages in the development of botanical drugs. Its lead product candidate is Thykamine, a Phase IIa clinical trial product for the treatment of ulcerative colitis and atopic dermatitis. The company also develops Pantoprazole Magnesium for the treatment of gastric or duodenal ulcers; Cleo-35 for the treatment of hormonal acne in women; and value-added products for dermo-cosmetics. In addition, it acquires drug and health product licenses; and distributes pharmaceutical products. Devonian Health Group Inc. has a strategic alliance with CannTx Life Sciences Inc. for the development of cannabinoid-based pharmaceutical drugs. The company was incorporated in 2015 and is headquartered in Québec, Canada.